danazol has been researched along with ecallantide in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Firszt, R; Frank, MM | 1 |
| Bork, K | 1 |
| Bork, K; Bowen, T; Boysen, H; Craig, T; Farkas, H; Grumach, A; Katelaris, CH; Lockey, R; Longhurst, H; Lumry, W; Magerl, M; Martinez-Saguer, I; Maurer, M; Nast, A; Pawankar, R; Pürsün, EA; Ritchie, B; Zuraw, B | 1 |
| Banerji, A; Bernstein, JA; Busse, P; Christiansen, S; Craig, T; Davis-Lorton, M; Frank, MM; Li, HH; Lumry, WR; Riedl, M; Zuraw, B | 1 |
2 review(s) available for danazol and ecallantide
| Article | Year |
|---|---|
An overview of novel therapies for acute hereditary angioedema.
Topics: Acute Disease; Adrenergic beta-Antagonists; Androgens; Antifibrinolytic Agents; Bradykinin; Bradykinin Receptor Antagonists; Complement C1 Inhibitor Protein; Danazol; Hereditary Angioedema Type III; Hereditary Angioedema Types I and II; Hormone Antagonists; Humans; Kallikreins; Peptides; Tranexamic Acid | 2010 |
Current management options for hereditary angioedema.
Topics: Angioedemas, Hereditary; Bradykinin; Complement C1 Inhibitor Protein; Danazol; Disease Management; Humans; Oxandrolone; Peptides; Plasma; Recombinant Proteins; Stanozolol | 2012 |
2 other study(ies) available for danazol and ecallantide
| Article | Year |
|---|---|
[WAO Guideline for the Management of Hereditary Angioedema].
Topics: Allergy and Immunology; Angioedemas, Hereditary; Bradykinin B2 Receptor Antagonists; Child; Child, Preschool; Complement C1 Inhibitor Protein; Danazol; Diagnosis, Differential; Evidence-Based Medicine; Female; Humans; International Cooperation; Kallikreins; Male; Patient Care Planning; Peptides; Practice Guidelines as Topic; Pregnancy; Recombinant Proteins; Social Support | 2015 |
Management of Children With Hereditary Angioedema Due to C1 Inhibitor Deficiency.
Topics: Adolescent; Angioedemas, Hereditary; Anti-Inflammatory Agents, Non-Steroidal; Antifibrinolytic Agents; Bradykinin; Child; Complement C1 Inactivator Proteins; Complement C1 Inhibitor Protein; Danazol; Genetic Testing; Humans; Patient Care Team; Patient Education as Topic; Peptides; Recombinant Proteins; Tranexamic Acid | 2016 |